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Abstract
Background:  The study of cost-effectiveness comparisons between competing medical
interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences
between the various approaches can be subtle, and one purpose of this article is to clarify some
important distinctions.
Discussion:  We discuss alternative measures in the framework of individual, patient-level,
incremental net benefits. In particular we examine the probability of cost-effectiveness for an
individual, proposed by Willan.
Summary: We argue that this is a useful addition to the range of cost-effectiveness measures, but
will be of secondary interest to most decision makers. We also demonstrate that Willan's
proposed estimate of this probability is logically flawed.
Background
The study of cost-effectiveness comparisons between com-
peting medical interventions has led to a variety of pro-
posals for quantifying cost-effectiveness. Although the
most widely used measure is still the incremental cost-ef-
fectiveness ratio (ICER), there is increasing preference for
the cost-effectiveness acceptability curve (CEAC). Willan
[1] has recently proposed an alternative that he calls the
probability of cost-effectiveness.
The differences between these various approaches can be
subtle, and further complexity is introduced by some au-
thors preferring a Bayesian formulation over more tradi-
tional frequentist analysis. One purpose of this article is to
clarify some important issues, concerning (a) the perspec-
tives of different decision makers and (b) the distinction
between the true value of an unknown parameter and a
statistical inference about that parameter.
Discussion
We first review various approaches to measuring cost-ef-
fectiveness, including the ICER, the mean incremental net
benefit, and the measure proposed by Willan [1]. We then
contrast these measures and argue that Willan's proposal
is of only secondary interest to a health care provider. All
of the cost-effectiveness measures are in practice unknown
parameters that must be estimated from data, and we next
consider inference about these measures from both the
frequentist and Bayesian approaches. Finally, a funda-
mental flaw in the estimator proposed by Willan [1] for
his probability of cost-effectiveness is exposed.
Measures of cost-effectiveness
We consider two competing treatments, drugs, or other
health technologies, which we refer to as Treatment 1 and
Treatment 2. Conventionally, Treatment 1 is often the
standard treatment whereas Treatment 2 is a new or com-
parator treatment. In reality there will usually be far more
than two competing treatments for any condition, but for
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the purpose of this article it is enough to consider, like
Willan [1], just two treatments.
A little notation is necessary. Let Ci be the cost associated
with an individual patient when given Treatment i, and let
Ei be the value of an appropriate effectiveness measure as-
sociated with that patient when given Treatment i. Now it
is important to recognise variation between patients. One
patient will incur different costs and experience different
effectiveness from another. Therefore, Ci and Ei are ran-
dom quantities, which we interpret as the cost and effec-
tiveness under Treatment i for an individual patient
randomly drawn from the population of all patients under
consideration. The probability distributions of these ran-
dom quantities describes how they vary over the popula-
tion.
In order to compare cost-effectiveness between the two
treatments, we require a way to link costs to effectiveness,
and this is done through a decision-maker's willingness to
pay coefficient K. Formally, the decision-maker is prepared
to pay K units of money to obtain one unit of effective-
ness. Therefore, the net benefit of Treatment i for an indi-
vidual (random) patient is
Bi(K) = K Ei - Ci.
This expresses net benefit on the monetary scale by con-
verting the Ei units of effectiveness into K Ei units of mon-
ey before subtracting the cost Ci. (We could equally
express net benefit on the effectiveness scale as Ei - Ci/K,
but the two approaches are clearly formally equivalent.)
The notation also emphasises the dependence of the net
benefit on the decision-maker's willingness to pay coeffi-
cient K.
Treatment 2 would be clearly more cost-effective than
Treatment 1 for an individual (random) patient if B2(K) >
B1(K). This can be expressed simply in terms of the indi-
vidual incremental net benefit (individual INB)
DB(K) = B2(K) - B1(K) = K DE - DC,
where DE = E2 - E1 and DC = C2 - C1 are the increments in
effectiveness and cost, respectively.
If all patients were the same, and experienced the same
costs and effectiveness, then the individual INB would be
the same for all patients, and could then be called the INB.
Then the comparison of treatments would become trivial.
The INB would quantify the gain (if positive) or loss (if
negative) per patient that would result from switching
from Treatment 1 to Treatment 2. Treatment 2 would
clearly be more cost-effective than Treatment 1 if, and
only if, the INB was positive.
However, patients will vary, and the consequence of this
is that individual INB will vary between patients, and
there is no single value to represent the comparison be-
tween the two treatments. Across the population, there is
a probability distribution of individual INB.
The measures of cost-effectiveness that are in widespread
use in health economics are based on the mean of this dis-
tribution. We denote the population mean incremental net
benefit (mean INB) by ∆ B(K). The standard notation in
probability theory for a mean or expected value is , so the
mean incremental net benefit is
∆ B(K) = (DB(K)) = K ∆ E - ∆ C,
where ∆ E = (DE) and ∆ C = (DC) are the population
mean increments in effectiveness and cost. Then Treat-
ment 2 is defined to be more cost-effective than Treatment
1, in terms of the population mean, if ∆ B(K) > 0.
The incremental cost-effectiveness ratio (ICER) can be ex-
pressed as
ρ  = ∆ C/∆ E,
and we can see that ∆ B(K) > 0, i.e. Treatment 2 is more
cost-effective than Treatment 1, if ρ  < K and ∆ E > 0, or if ρ
> K and ∆ E < 0.
The probability of cost-effectiveness as proposed by Wil-
lan [1] is the probability that an individual (random) pa-
tient will have a positive individual INB. We can denote
this by θ (K) = Pr(DB(K) > 0). It can also be seen as the pro-
portion of all patients in the population who have posi-
tive individual INBs.
∆ B(K) and θ (K) are just two summary measures of the dis-
tribution of net benefit in the population. If the distribu-
tion is symmetric about its mean, as shown for instance in
Figure 1, then the two measures will be in agreement, in
the sense that ∆ B(K) will be positive if and only if θ (K) is
greater than 0.5.
Thus, the distribution represented by the solid curve in
Figure 1 has mean ∆ B(K) = 1.3 and θ (K) = 0.903, so that
Treatment 2 is more cost-effective in terms of having a
higher mean INB and the proportion of patients who will
achieve a higher individual INB under Treatment 2 is
90.3%. Conversely, the distribution represented by the
dashed curve has ∆ B(K) = -0.7 and θ (K) = 0.242, so the
mean INB under Treatment 2 is now less than under Treat-
ment 1, and only 24.2% of patients will obtain a higher
individual INB under Treatment 2.BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/5
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If, however, the distribution is not symmetric, then it is
quite possible for the two measures to give apparently
contradictory indications of relative cost-effectiveness.
Figure 2 shows another two possible distributions. In the
distribution shown as a solid line, ∆ B(K) = 0.2 and θ (K) =
0.414, so the mean INB is positive but only 41.4% of pa-
tients actually have a higher individual INB under Treat-
ment 2. This is because those 41.4% include an
appreciable proportion who obtain large positive individ-
ual INBs of 2 or more, whereas although the other 58.6%
have negative individual INBs they never experience a val-
ue beyond -1. Conversely, in the distribution shown as a
dashed line in Figure 2, ∆ B(K) = -1 and θ (K) = 0.682, so
that the mean INB is negative but 68.2% of patients have
a positive individual INB.
Which measure is best?
It is well-known in health economics that, from the per-
spective of a health care provider needing to decide which
treatment to apply to the population of patients in their
care, it is the mean cost and effectiveness over the whole
population that matters [2]. This is because the decision is
to apply to the whole population. The health care provid-
er will have to pay a cost equal to the total of all the costs
for individual patients under the chosen treatment, and
when expressed on a per-patient basis this is the popula-
tion mean cost. For a similar reason, the per-patient mean
effectiveness under the chosen treatment measures the
benefit that the health care provider obtains for that cost
in terms of improved health for the patients in its care. If
the health care provider's willingness to pay coefficient is
K, then the appropriate measure of relative cost-effective-
ness is the mean INB ∆ B(K), and the correct decision is to
fund Treatment 2 if ∆ B(K) > 0 or Treatment 1 if ∆ B(K) < 0
[3].
As discussed in the previous section, this can be expressed
in terms of comparing the ICER ρ  with K, but that ap-
proach is more complex, since the comparison depends
on the sign of ∆ E.
From the perspective of a health care provider, then, need-
ing to make a decision between two treatments, the deci-
sion rests on mean INB, and in fact only on its sign. There
is no role for Willan's θ (K). As we have seen in Figure 2,
the wrong decision could be made if it were based on
θ (K).
Willan [1] says, "The use of θ (K) should be helpful to pol-
icy-makers". We agree, in the sense that it does give extra
information about the distribution of individual INBs in
the population, but as such it is of secondary interest, on-
ly. It should not be used as the basis of the actual decision.
Nevertheless, we believe that in general an understanding
of the distribution of individual INBs in the population is
useful ancillary information that may be helpful to a deci-
sion-maker in the subsequent implementation of the de-
cision.
The perspective of a health care provider is not necessarily
the only one of interest. An individual clinician wishing to
decide how to treat an individual patient may be willing
to regard that patient as randomly drawn from a large
population, and might be interested in θ (K). However,
the situations shown in Figure 2 argue for caution. Con-
sider for instance the dashed curve. The patient is substan-
tially more likely to have a positive individual INB than a
negative one, and this may seem to suggest prescribing
Treatment 2. There is, however, a risk of a large negative
INB, corresponding to the patient having a very much
worse outcome with Treatment 2 than with Treatment 1.
In our opinion, the mean INB is as relevant to an individ-
Figure 1
Two symmetric distributions of net benefit.
Figure 2
Two skewed distributions of net benefit.BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/5
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ual decision as to the group decision of a health care pro-
vider.
Inference about cost-effectiveness
The measures of cost-effectiveness described in the pre-
ceding section are all unknown in practice because they
depend on the unknown distribution of individual INBs
for patients in the population. From the statistical point of
view they are unknown parameters. In order to learn
about them, we will need to obtain some relevant evi-
dence. This might, for instance, as supposed in Willan [1],
consist of observations of actual costs and effectiveness for
a sample of patients in a clinical trial.
We then need to construct appropriate methods of statis-
tical inference for parameters of interest, based on the da-
ta. There is a substantial literature on this topic. Based on
data from a clinical trial, various authors have presented
estimators and confidence intervals for the ICER [4–12],
and comparable inferences for the mean INB [3,13]. All of
these references employ the frequentist approach to statis-
tical inference. Analyses under a Bayesian approach have
also been given [14–18]. The fact that the ICER is a ratio,
together with the way its interpretation changes as the sign
of ∆ E changes, mean that inference about the mean INB is
generally much more straightforward [17,18].
Inference about the mean INB is generally presented by
means of a Cost-Effectiveness Acceptability Curve (CEAC)
[16–22]. As introduced by van Hout et al [19], the CEAC
plots the probability that mean INB is positive against K.
The value of such a graph lies partly in the difficulty of
specifying K in practice. Decision-makers are generally re-
luctant to commit themselves to an explicit willingness to
pay, and plotting against K allows them to assess the rela-
tive cost-effectiveness of the two treatments over a range
of values of K. Strictly, the probability that ∆ B(K) is posi-
tive can only be a Bayesian inference, since only in the
Bayesian approach is it possible to assign probability dis-
tributions to unknown parameters. The frequentist ana-
logue is to consider the P-value of a significance test of the
null hypothesis that ∆ B(K) < 0 [17,23]. It is important to
remember, as always, that the interpretation of a P-value
for a null hypothesis is much less direct and meaningful
than the Bayesian probability that the hypothesis is true.
In its more natural Bayesian form, the CEAC states, for
given K, the probability, based on the available evidence, that
the true value of the unknown parameter ∆ B(K) is posi-
tive. It therefore states, for given K, the probability, based
on the available evidence, that Treatment 2 is more cost-ef-
fective than Treatment 1, from the perspective of a health
care provider needing to make a decision between the two
treatments. In presenting the CEAC in practice, authors
have tended to assert that the CEAC states, for given K, the
probability that Treatment 2 is more cost-effective than
Treatment 1, omitting to refer to the fact that this proba-
bility is based on available evidence, and omitting to state
the decision context. Willan [1] objects to this presenta-
tion of the CEAC as giving 'the probability of cost-effec-
tiveness'. He writes:
"The interpretation that the acceptability curve is the
probability that the intervention is cost-effective is not en-
tirely accurate and could easily be misunderstood by pol-
icy makers. Consider the situation in which the observed
INB for treatment is very small, but due to a very large
sample size the acceptability curve at the value of λ  [our
K] of interest is 0.99. Attaching the label "the probability
that the intervention is cost-effective" to this quantity
could mislead policy makers into thinking that treatment
is highly beneficial compared to the standard. What, in
fact, is high is our confidence that the INB, however small,
is not zero."
We agree that to refer to the CEAC as simply 'the probabil-
ity of cost-effectiveness', or 'the probability that Treatment
2 is more cost-effective than Treatment 1', is potentially
misleading if its dependence on the available evidence
and on the decision context is not clear. We advocate that
the phrase 'based on available evidence' should be used to
emphasise the first point, or for a technical audience the
Bayesian formulation of 'the posterior probability of cost-
effectiveness' would be appropriate. It might be helpful
also to emphasise that we are judging cost-effectiveness
from the perspective of a health care provider needing to
decide between two treatments, although this context has
been so pervasively adopted in health economics that we
believe it can be taken as understood.
Willan proposes that θ (K) should more properly be called
'the probability of cost-effectiveness', but to use the phrase
for θ (K) without further qualification would be equally
misleading to policy makers. To parallel the above quota-
tion from Willan [1], consider the situation in which the
mean INB is positive but small, but due to there being very
little between-patient variation we find θ (K) = 0.99. At-
taching the label 'the probability that the intervention is
cost-effective' to this quantity could mislead policy mak-
ers into thinking that treatment is highly beneficial com-
pared to the standard. What, in fact, is high is the
proportion of patients in the population for whom the in-
dividual INB, however small, is positive.
Neither measure asserts the degree to which one treatment
is 'highly beneficial' compared to the other. Both are con-
cerned only with t he sign of INB.  The C EAC gives the
probability, based on available evidence, that the mean
INB is positive, while θ (K) gives the probability that an in-
dividual INB is positive.BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/5
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Willan [1] further objects to the fact that the CEAC chang-
es as we get more information, because it is a statistical in-
ference. As we get more evidence, our uncertainty about
the sign of ∆ B(K) for a given value of K will decrease until
we become certain either that ∆ B(K) is positive (whereup-
on the CEAC will tend to 1) or that it is negative (in which
case the CEAC will tend to 0). This is entirely natural, and
we do not understand this objection.
Willan's θ (K) is a probability in a different sense, because
it is a population parameter, not an inference about a
population parameter. Inferences change as we get more
data, while the true values of the underlying parameters
remain fixed, but unknown. This does not make θ (K) in
any sense a superior kind of probability. It happens that
Willan is interested in inference about a parameter that
can itself be considered as a probability (although we be-
lieve it would be more helpful to call it a proportion, i.e.
the proportion of patients in the population with positive
individual INBs). To make inference about it, he provides
an estimator (although, as we shall see below, that estima-
tor is logically flawed), but he could have considered cal-
culating a P-value for the null hypothesis that θ (K) > 0.5.
That would be analogous to the CEAC, and would change
with the available data in the same way.
Willan's estimator
Willan proposes an estimator of θ (K) based on data com-
prising observed costs and effectiveness values for a sam-
ple of nS patients given the standard, treatment 1, and
another sample of nT patients given the intervention,
treatment 2. Now since these data do not include any ob-
servations in which the same patient is given both treat-
ments, it is completely impossible to learn the true value
of θ (K), no matter how large nS and nT might be.
It is easy to demonstrate this impossibility with a simple
example. Suppose that we have enormous samples such
that we learn the true distribution in the population of
costs and effects for treatment 1 and the true distribution
of costs and effects for treatment 2. In particular, we will
also learn the true distribution of net benefits Bi(K) for
each treatment. Suppose that the value of K is given and
that the distribution of the net benefit B1(K) under treat-
ment 1 is N(0,1) (i.e. normal with mean 0 and variance
1), while the distribution of net benefit B2(K) under treat-
ment 2 is N(1,1). With all this information we know these
distributions, and so we know exactly that ∆ B(K) = 1. We
therefore know with certainty that treatment 2 is more
cost-effective than treatment 1 for a health care provider
with the given value of K.
Even with all this information we do not know θ (K), be-
cause this depends on how correlated B1(K) and B2(K) are
in the population. At one extreme, they might be perfectly
positively correlated, such that for every individual in the
population it is true that B2(K) = B1(K) + 1. Then θ (K) =
1, because the individual INB is positive for every patient.
At the other extreme we might have perfect negative corre-
lation, so that for every individual in the population we
have B2(K) = 1 - B1(K). Then treatment 2 is more cost-ef-
fective for all those individuals for whom B1(K) < 0.5. The
proportion of such individuals in the population is
69.15%, and so θ (K) = 0.6915.
Willan's estimator effectively assumes that B1(K) and
B2(K) are independent in the population, and for our ex-
ample this implies that DB(K) is distributed as N(1,2),
with the result that θ (K) = 0.7633. The assumption is ar-
bitrary and completely unsupported. Indeed one might
imagine that in practice there would be quite strong corre-
lations, on the basis that a patient who responds well to
one treatment might respond relatively well to the other,
and similarly for costs. But we reiterate that there is abso-
lutely no evidence about this correlation in the data which
Willan supposes are available. Indeed for most kinds of
intervention it is impractical to test two treatments on the
same patient, and even when this is possible we must ex-
pect the picture to be complicated by cross-over effects.
What Willan [1] actually estimates is the probability that
a randomly chosen patient given treatment 1 will obtain
a higher net benefit than another randomly chosen patient
given treatment 2. This is an entirely different measure
from θ (K) and we cannot imagine that it is of fundamen-
tal interest to any policy maker.
Summary
1. From the perspective of a health care provider needing
to decide which of two treatments to fund, it is the mean
cost and mean effectiveness, over the whole population of
patients within the provider's remit, that are of primary
concern. This leads to the mean INB ∆ B(K) as the appro-
priate measure of cost-effectiveness, and to the specific
question of whether ∆ B(K) is positive.
2. Any measure of cost-effectiveness is a property of the
population of patients under consideration, and is an un-
known parameter. We make statistical inferences about
parameters, based on available evidence. The true value of
the parameter is fixed, independent of the available evi-
dence, but unknown. Any statistical inference statement
about the parameter is liable to change as the evidence
changes. The CEAC plots the probability, based on availa-
ble evidence, that ∆ B(K) > 0, and is the most relevant in-
ference for a health care provider needing to decide
between two treatments. Because it is an inference, the
CEAC depends on the data.BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/5
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3. When reporting the CEAC in practice, its dependence
on the data should be made clear by referring to it in such
phrases as 'the probability of cost-effectiveness based on
available evidence' or 'the posterior probability of cost-ef-
fectiveness'. It may also be useful to emphasise that cost-
effectiveness is being judged from the perspective of a
health care provider needing to decide which of two treat-
ments to fund.
4. Willan's probability of cost-effectiveness θ (K) may be
useful to a decision maker in the same way as knowing
other aspects of the distribution of individual INBs in the
population would be useful, but it will generally be of sec-
ondary importance to the sign of ∆ B(K). Since θ (K) is a pa-
rameter it does not depend on the data, but it is unknown,
and any statistical inference about it will depend on the
data.
5. θ (K) should not be referred to simply as 'the probability
of cost-effectiveness' either, and we advise calling it, for ex-
ample, 'the proportion of patients for whom the treat-
ment is cost-effective'. The fact that it is an unknown
parameter should be emphasised, by a formulation such
as 'based on available evidence, the proportion ... is esti-
mated to be ...'
6. The proposed estimator of θ (K) given by Willan [1] is
flawed. This parameter cannot be estimated consistently
from the kind of data considered by Willan. His proposed
estimate is in fact a probability concerning two randomly
selected future patients, and is of doubtful interest to any
decision maker.
Conclusion
In conclusion, therefore, we reiterate the appropriateness
of the CEAC as the primary comparator of relative cost-ef-
fectiveness between two treatments from the perspective
of a health care provider. Willan's 'probability of cost-ef-
fectiveness' would be of only secondary value in evidence
presented to policy makers, and his proposed estimator of
that probability is fatally flawed. However, we agree with
Willan that assessments of cost-effectiveness should be
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